J&J Halts Study of Doribax Antibiotic on Higher Death Rate

Johnson & Johnson halted a clinical trial of its antibiotic Doribax after more pneumonia patients who took the product died and fewer were cured, regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.